Indeed, a phase Ib/II clinical trial is currently ongoing to evaluate the side effects and best dose of PRIMA-1 analog APR-246 when given along with azacitidine in treating patients with mutated TP53 mutant myeloid cancers, as well as a phase III study to compare the rate of complete response (CR) and duration of CR in patients with TP53-mutated Myelodysplastic Syndromes [43]. Here, TP53 is linked to myelodysplastic syndrome.